natgillin/translations-raw huggingface dataset:
Anaemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a physician's evaluation of the individual patient's clinical course and condition is necessary. 
Simptomi anemije i njezine posljedice mogu varirati ovisno o dobi, spolu i sveukupnom opterećenju izazvanom bolešću; potrebna je liječnička procjena kliničkog tijeka liječenja i stanja svakog pojedinog bolesnika.
Nervous system disorders Headache 
Poremećaji živčanog sustava
Erythropoietin is a glycoprotein that stimulates the formation of erythrocytes from its committed progenitors. 
Eritropoetin je glikoprotein koji potiče stvaranje eritrocita iz usmjerenih progenitorskih stanica.
In most cases, a fall in serum ferritin values simultaneous with a rise in packed cell volume is observed (see section 4.4). 
U većini slučajeva primijećen je pad serumskih vrijednosti feritina istodobno s porastom hematokrita (vidjeti dio 4.4).
Roche S.p.A. 
Italia Roche S.p.A.
Adverse reactions are listed according to MedDRA system organ class and frequency category. 
Nuspojave su navedene prema MedDRA podjeli organskih sustava i kategoriji učestalosti.
An individual patient data based meta-analysis, which included data from all 12 controlled clinical studies in anaemic cancer patients conducted with NeoRecormon (n=2301), showed an overall hazard ratio point estimate for survival of 1.13 in favour of controls (95 % CI 0.87, 1.46). 
Meta-analiza podataka pojedinih bolesnika koja je uključivala podatke iz svih 12 kontroliranih kliničkih ispitivanja s lijekom NeoRecormon u anemičnih bolesnika oboljelih od raka (n=2301), pokazala je procjenu omjera ukupnog rizika za preživljenje od 1,13 u korist kontrolnih skupina (95% CI 0,87; 1,46).
In case of intravenous administration, the solution should be injected over approx. 2 minutes, e.g. in haemodialysis patients via the arterio-venous fistula at the end of dialysis. 
U slučaju intravenske primjene, otopina se treba injicirati kroz oko 2 minute, primjerice u bolesnika na dijalizi putem arteriovenske fistule na kraju hemodijalize.
One vial contains 50,000 IU (international units) epoetin beta. 
Jedna bočica sadrži 50 000 IU (internacionalnih jedinica) epoetina beta.
The indication for NeoRecormon treatment and, if given, the single dose should be determined from the required amount of pre-donated blood and the endogenous red cell reserve according to the following graphs. 
Indikaciju za terapiju lijekom NeoRecormon i pojedinačnu dozu treba odrediti iz potrebne količine predonirane krvi i endogene rezerve eritrocita, prema sljedećim grafikonima:
A tendency towards increased risk estimates for all cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed (see sections 4.2 and 4.4). 
Primijećena je tendencija povećanja procijenjenog rizika od smrti zbog bilo kojeg uzroka te kardiovaskularnih i cerebrovaskularnih događaja povezanih s višim kumulativnim dozama lijekova za stimulaciju eritropoeze, neovisno o dijabetesu i statusu dijalize (vidjeti dijelove 4.2 i 4.4).
NeoRecormon in pre-filled syringe is a sterile but unpreserved product. 
NeoRecormon otopina u napunjenoj štrcaljki je sterilna, ali bez konzervansa.
After administration of epoetin beta, the number of erythrocytes, the Hb values and reticulocyte counts increase as well as the 59Fe-incorporation rate. 
Nakon primjene epoetina beta raste broj eritrocita, vrijednosti hemoglobina, broj retikulocita te brzina ugradnje željeza 59Fe.
In case anti-erythropoietin antibodymediated PRCA is diagnosed, therapy with NeoRecormon must be discontinued and patients should not be switched to another erythropoietic protein (see section 4.4). 
U slučaju dijagnosticiranja PRCA-e, terapiju lijekom NeoRecormon treba odmah prekinuti i takve bolesnike se ne smije nastaviti liječiti bilo kojim drugim eritropoetinskim proteinom (vidjeti dio 4.4).
Blood and the lymphatic system disorders 
Poremećaji krvi i limfnog sustava Tromboza šanta
Erythropoietin is a growth factor that primarily stimulates red cell production. 
Eritropoetin je faktor rasta koji primarno stimulira proizvodnju crvenih krvnih stanica.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
embrionalni/fetalni razvoj, porod ili postnatalni razvoj (vidjeti dio 5.3).
This is dissolved with the contents of the accompanying solvent ampoule by means of a reconstitution and withdrawal device according to the instructions given below. 
Liofilizat se otapa sa sadržajem priložene ampule s otapalom, pomoću nastavka za pripremu i izvlačenje pripremljene otopine, a prema niže navedenim uputama.
The following instructions explain how to give an injection of NeoRecormon. 
U sljedećim se uputama objašnjava kako injicirati lijek NeoRecormon.
Treatment for increasing the amount of autologous blood The solution is administered intravenously over approx. 2 minutes or subcutaneously. 
Liječenje u svrhu porasta količine autologne krvi Otopina se daje intravenski kroz 2 minute ili supkutano.
The following Instructions for Use explains how to give an intravenous injection of NeoRecormon. 
U sljedećim se uputama objašnjava kako primijeniti intravensku injekciju lijeka NeoRecormon.
NeoRecormon contains up to 40 mg benzyl alcohol as a preservative per solvent ampoule and must therefore not be given to infants or young children up to three years old. 
NeoRecormon sadrži do 40 mg konzervansa, benzilnog alkohola u ampuli s otapalom pa se stoga ne smije davati dojenčadi ni djeci u dobi do tri godine.
One ampoule contains 10 ml solvent (water for injections with benzyl alcohol and benzalkonium chloride as preservatives). 
Jedna ampula sadrži 10 ml otapala (voda za injekcije s konzervansima benzilnim alkoholom i benzalkonijevim kloridom).
Do not use the syringe or the needle if the expiration date has passed. 
Nemojte upotrijebiti štrcaljku ni iglu ako im je istekao rok valjanosti.
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ(I) BIOLOŠKE(IH) DJELATNE(IH) TVARI I PROIZVOĐAČ(I) ODGOVORAN(ODGOVORNI) ZA PUŠTANJE SERIJE LIJEKA U PROMET
Your doctor may do regular blood tests to check: · your potassium level. 
Vaš liječnik može provoditi redovite krvne pretrage zbog provjere:
If any of these apply to you, or might apply, tell your doctor. 
Ako se bilo što od nabrojanog odnosi ili bi se moglo odnositi na Vas, obavijestite svog liječnika.
If you think you have been injected more NeoRecormon than you should, contact your doctor. 
Ako mislite da vam je ubrizgana veća doza lijeka NeoRecormon nego što je trebalo, obratite se svom liječniku.
Check that the solution is clear, colourless and practically free from particles. 
Provjerite je li otopina bistra, bezbojna i skoro potpuno bez vidljivih čestica.
If, after 8 weeks of therapy, the haemoglobin value has not increased by at least 1 g/dl (0.62 mmol/l), response is unlikely and treatment should be discontinued. 
Ako se ni nakon 8 tjedana terapije vrijednost hemoglobina ne poveća za barem 1 g/dl (0,62 mmol/l), terapijski odgovor nije izgledan i terapiju treba prekinuti.
A rise in haemoglobin of greater than 2 g/dl (1.25 mmol/l) over a four week period should be avoided. 
Treba izbjegavati porast hemoglobina veći od 2 g/dl (1,25 mmol/l) unutar perioda od četiri tjedna.
For subcutaneous injection, clean the skin at the site of injection using an alcohol wipe. 
Za supkutanu injekciju kožu na mjestu injiciranja očistite vaticom natopljenom alkoholom.
Your doctor will take regular blood samples. 
Liječnik će Vas redovito slati na krvne pretrage.
Almost all patients have to be treated with iron supplements during their NeoRecormon therapy. 
Gotovo svi bolesnici tijekom liječenja lijekom NeoRecormon moraju uzimati nadomjesne preparate željeza.
After dissolving, NeoRecormon is injected under the skin (subcutaneously) or into a vein (intravenously). 
Nakon otapanja NeoRecormon se ubrizgava pod kožu (supkutano) ili u venu (intravenski).
· If you have any further questions, ask your doctor or pharmacist. 
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
Expel air from the syringe and needle by holding the syringe vertically and gently pressing the plunger upwards. 
Istjerajte zrak iz štrcaljke i igle držeći štrcaljku uspravno i lagano potiskujući klip prema gore.
For both routes of administration, the maximum dose should not exceed 720 IU/kg per week. 
Maksimalna doza kod oba puta primjene ne smije prijeći 720 IU/kg tjedno.
Benzyl alcohol, Benzalkonium chloride, Water for injections. 
benzalkonijev klorid, voda za injekcije.
In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer. 
Imajući u vidu gore navedeno, prilikom liječenja anemije kod bolesnika s rakom, u pojedinim kliničkim situacijama prednost treba dati transfuziji krvi.
· Adults with symptomatic anaemia receiving chemotherapy for cancer 
• Odrasli bolesnici sa simptomatskom anemijom koji primaju kemoterapiju zbog raka
If the haemoglobin value has not increased by at least 1 g/dl (0.62 mmol/l), a doubling of the weekly dose should be considered. 
Ako se razina hemoglobina ne poveća za barem 1 g/dl (0,62 mmol/l), treba razmotriti udvostručenje tjedne doze.
NeoRecormon Multidose contains benzyl alcohol as a preservative and must therefore not be given to infants or young children up to three years old. 
NeoRecormon Multidose sadrži konzervans benzilni alkohol pa se stoga ne smije davati djeci u dobi do 3 godine.
The maximum dose should not exceed 1600 IU/kg body weight per week for intravenous or 1200 IU/kg per week for subcutaneous administration. 
Ne smije se prekoračiti maksimalna doza od 1600 IU/kg tjel. mase tjedno pri intravenskoj primjeni te 1200 IU/kg tjel. mase tjedno pri supkutanoj primjeni.
Inject NeoRecormon solution. 
Injicirajte NeoRecormon otopinu.
·Do not hold or push on the plunger while inserting needle. 
Nemojte držati ni potiskivati klip dok uvodite iglu.
· The reconstituted solution may be stored for 1 month in a refrigerator at 2°C - 8°C. 
Pripremljena se otopina može čuvati 1 mjesec u hladnjaku na 2°C - 8°C.
It acts as a mitosis stimulating factor and differentiation hormone Epoetin beta, the active substance of NeoRecormon, is identical in its amino acid and carbohydrate composition to erythropoietin that has been isolated from the urine of anaemic patients. 
Epoetin beta, djelatna tvar lijeka NeoRecormon, je, po svom sadržaju aminokiselina i ugljikohidrata, identičan eritropoetinu izoliranom iz urina anemičnih bolesnika.
per week. 
Vaše tjelesne mase tjedno.
17 There may be a little bleeding at the injection site. 
Nakon injiciranja 17. Na mjestu injiciranja možete primijetiti lagano krvarenje.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an openlabel study. 
Preživljenje i napredovanje tumora ispitivani su u pet velikih kontroliranih studija u kojima je sudjelovalo ukupno 2833 bolesnika.
Rarely, epoetin beta treatment-related skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. 
Rijetko se mogu javiti kožne reakcije povezane s liječenjem epoetinom beta poput osipa, pruritusa, urtikarije ili reakcija na mjestu primjene.
Always use this medicine exactly as your doctor has told you. 
Kako primjenjivati NeoRecormon Uvijek primijenite ovaj lijek točno onako kako Vam je rekao liječnik.
More severe cases have been observed with long-acting epoetins.At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. 
U trenutku propisivanja lijeka bolesnike je potrebno savjetovati o znakovima i simptomima te pomno pratiti imaju li kožne reakcije.
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l). 
Varijabilnost hemoglobina treba rješavati korekcijom doze, uzimajući u obzir da je ciljni raspon hemoglobina od 10 g/dl (6,2 mmol/l) do 12 g/dl (7,5 mmol/l).
blood volume [ml] = 44 [ml/kg] x body weight [kg] + 1600 [ml] (body weight ³ 45 kg) 
volumen krvi [ml] = 44 [ml/kg] x tjel. masa [kg] + 1600 [ml]
NeoRecormon 2000 IU solution for injection in pre-filled syringe NeoRecormon 3000 IU solution for injection in pre-filled syringe NeoRecormon 4000 IU solution for injection in pre-filled syringe NeoRecormon 5000 IU solution for injection in pre-filled syringe NeoRecormon 6000 IU solution for injection in pre-filled syringe NeoRecormon 10,000 IU solution for injection in pre-filled syringe NeoRecormon 20,000 IU solution for injection in pre-filled syringe NeoRecormon 30,000 IU solution for injection in pre-filled syringe 
NeoRecormon 500 IU otopina za injekciju u napunjenoj štrcaljki NeoRecormon 2000 IU otopina za injekciju u napunjenoj štrcaljki NeoRecormon 3000 IU otopina za injekciju u napunjenoj štrcaljki NeoRecormon 4000 IU otopina za injekciju u napunjenoj štrcaljki NeoRecormon 5000 IU otopina za injekciju u napunjenoj štrcaljki NeoRecormon 6000 IU otopina za injekciju u napunjenoj štrcaljki NeoRecormon 10 000 IU otopina za injekciju u napunjenoj štrcaljki NeoRecormon 20 000 IU otopina za injekciju u napunjenoj štrcaljki NeoRecormon 30 000 IU otopina za injekciju u napunjenoj štrcaljki
Take hold of the stem and snap off away from you. 
Primite vrh ampule i odlomite ga u smjeru od sebe.
After 4 weeks, the doctor will do tests and, if the treatment response is not sufficient, your dose may be raised to 40 IU/kg per injection, given three times per week. 
Nakon 4 tjedna liječnik će napraviti pretrage i ako odgovor na terapiju nije zadovoljavajuć, doza se može povećati na 40 IU/kg po injekciji, tri puta tjedno.
Pre-filled syringe (Type I glass) with a tip cap and a plunger stopper (teflonised rubber). 
Napunjena štrcaljka (staklo tip I) sa zatvaračem vrha i čepom klipa (guma obložena teflonom).
- Treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy. 
Liječenje simptomatske anemije u odraslih bolesnika s nemijeloičnim zloćudnim bolestima koji primaju kemoterapiju.
· Pull the rubber cap off the end of the syringe (A). 
Povucite gumeni zatvarač sa štrcaljke (A).
Remove one needle from the pack, fix it on the syringe and remove the protective cap from the needle. 
Izvadite jednu iglu iz pakiranja, pričvrstite je na štrcaljku i uklonite pokrov s igle.
Clean the injection port as instructed by the provider. 
Kateter očistite prema uputama dobavljača.
Epoetin beta treatment-related headache and hypertension which can be treated with drugs are common (see section 4.4). 
Glavobolja i hipertenzija, povezane s liječenjem epoetinom beta, koje se mogu liječiti lijekovima su česte (vidjeti dio 4.4)
NeoRecormon should be administered either subcutaneously or intravenously in order to increase haemoglobin to not greater than 12 g/dl (7.5 mmol/l). 
NeoRecormon treba davati ili supkutano ili intravenski kako bi se razina hemoglobina povećala na razinu koja nije viša od 12 g/dl (7, 5 mmol/l).
In a randomised, double-blind, placebo-controlled study of 4,038 chronic renal failure patients not on dialysis with type 2 diabetes and haemoglobin levels ≤ 11 g/dL, patients received either treatment with darbepoetin alfa to target haemoglobin levels of 13 g/dL or placebo (see section 4.4). 
bolesnika s kroničnim zatajenjem bubrega i dijabetesom tipa 2 koji nisu bili na dijalizi, a razine hemoglobina su im bile ≤ 11 g/dl, bolesnici su primali ili darbepoetin alfa radi podizanja ciljnih razina hemoglobina na 13 g/dl, ili placebo (vidjeti dio 4.4).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABELS/AMPOULE 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICE/AMPULA
Withdraw all the solvent into the syringe. 
Izvucite svu količinu otapala u štrcaljku.
The liquid should be clear and colorless. 
Ona mora biti prozirna i bezbojna.
Shunt thromboses may occur, especially in patients who have a tendency to hypotension or whose arteriovenous fistulae exhibit complications (e.g. stenoses, aneurisms), see section 4.4. 
Može doći do tromboze šanta, poglavito u bolesnika sklonih hipotenziji ili u onih s komplikacijama arteriovenske fistule (npr. stenoze, aneurizme), vidjeti dio 4.4.
After 4 weeks, the doctor will do tests and, if the treatment response is not sufficient, your dose may be raised to 80 IU/kg per injection, given three times per week. 
Nakon 4 tjedna, liječnik će napraviti pretrage i ako odgovor na terapiju nije zadovoljavajući, doza se može povećati na 80 IU/kg po injekciji, tri puta tjedno.
Labelling of the stand 
Označavanje na kartonskom stalku
This leaflet was last revised in 
Ova uputa je zadnji puta revidirana u <{MM/GGGG}> <{mjesec GGGG}.>
· Check the expiration date on the syringe and the needle. 
Provjerite rok valjanosti na štrcaljki i igli.
Analysis of the individual components of the composite endpoints showed the following HR (95% CI): death 1.05 (0.92, 1.21), stroke 1.92 (1.38, 2.68), congestive heart failure (CHF) 0.89 (0.74, 1.08), myocardial infarction (MI) 0.96 (0.75, 1.23), hospitalisation for myocardial ischaemia 0.84 (0.55, 1.27), ESRD 1.02 (0.87, 1.18). 
(1,38; 2,68), kongestivno zatajenje srca 0,89 (0,74; 1,08), infarkt miokarda 0,96 (0,75; 1,23), hospitalizacija zbog ishemije miokarda 0,84 (0,55; 1,27), završna faza bolesti bubrega 1,02 (0,87;
Caution should be exercised when prescribing to pregnant women. 
Potreban je oprez prilikom propisivanja lijeka NeoRecormon trudnicama.
· Do not use if the expiration date has passed, if the syringe is dropped or damaged, or if the carton appears to be tampered with. 
● Nemojte upotrijebiti štrcaljku ako je istekao rok valjanosti, ako je štrcaljka pala ili je oštećena te ako postoje znakovi neovlaštenog rukovanja kutijom.
Only solutions which are clear or slightly opalescent, colourless and practically free of visible particles may be injected. 
Koristiti se smije samo otopina koja je bistra ili blago opalescentna, bezbojna i skoro potpuno bez vidljivih čestica.
· Keep this leaflet. 
Sačuvajte ovu uputu.
Clean the skin at the site of injection using an alcohol wipe. 
Očistite kožu na mjestu injiciranja vaticom natopljenom alkoholom.
Serum potassium and phosphate levels should be monitored regularly during NeoRecormon therapy. 
Vrijednosti kalija i fosfata u serumu tijekom primjene lijeka NeoRecormon moraju se redovito kontrolirati.
NeoRecormon 500 IU NeoRecormon 2000 IU NeoRecormon 3000 IU NeoRecormon 4000 IU NeoRecormon 5000 IU NeoRecormon 6000 IU NeoRecormon 10,000 IU NeoRecormon 20,000 IU NeoRecormon 30,000 IU solution for injection in pre-filled syringe Epoetin beta 
NeoRecormon 500 IU NeoRecormon 2000 IU NeoRecormon 3000 IU NeoRecormon 4000 IU NeoRecormon 5000 IU NeoRecormon 6000 IU NeoRecormon 10 000 IU NeoRecormon 20 000 IU NeoRecormon 30 000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
In chronic renal failure patients an increase in heparin dose during haemodialysis is frequently required during the course of therapy with NeoRecormon as a result of the increased packed cell volume. 
Tijekom terapije lijekom NeoRecormon u bolesnika s kroničnim zatajenjem bubrega često je za vrijeme hemodijalize potrebna viša doza heparina, kao rezultat porasta hematokrita.
MINIMUM PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA
The single dose thus determined is administered twice weekly over 4 weeks. 
Tako određena pojedinačna doza se daje dva puta tjedno kroz 4 tjedna.
· Do not touch the tip of the syringe. 
Nemojte dirati vrh štrcaljke.
The initial dose for injections under the skin is 20 IU per injection for every 1 kg of your body weight, given three times per week. 
Početna doza za injekcije pod kožu iznosi 20 IU na svaki kilogram Vaše tjelesne mase po injekciji, primijenjeno tri puta tjedno.
Misuse of NeoRecormon by healthy people may lead to an increase in blood cells and consequently thicken the blood. 
Zlouporaba lijeka NeoRecormon u zdravih ljudi može dovesti do povećanja broja vlastitih krvnih stanica i tako zgusnuti krv, što može dovesti do po život opasnih komplikacija na srcu ili krvnim žilama.
Caution should be exercised with escalation of NeoRecormon doses in patients with chronic renal failure. 
Potreban je oprez prilikom povećanja doza lijeka NeoRecormon u bolesnika s kroničnim zatajenjem bubrega.
If the haemoglobin exceeds 12 g/dl (7.5 mmol/l), the dose should be reduced by approximately 25 to 50 %. 
Ako hemoglobin prelazi razinu od 12 g/dl (7,5 mmol/l), dozu treba smanjiti za otprilike 25 do 50%.
Premature infants who have been transfused before the start of treatment with NeoRecormon are not likely to benefit as much as untransfused infants. 
Nedonoščad koja je prethodno primila transfuziju, najvjerojatnije neće imati onoliku korist od liječenja lijekom NeoRecormon kao nedonoščad koja nije primila transfuziju.
Hypertensive crisis with encephalopathy-like symptoms (e.g. headaches and confused state, sensorimotor disorders - such as speech disturbance or impaired gait - up to tonoclonic seizures) may also occur in individual patients with otherwise normal or low blood pressure (see section 4.4). 
U pojedinih bolesnika s normalnim ili niskim krvnim tlakom, može doći do hipertenzivnih kriza sa simptomima sličnim encefalopatiji (npr. glavoboljama i konfuznim stanjem, poremećajima osjeta i motorike - poput poremećaja govora ili nesigurnog hoda - sve do toničko-kloničkih napadaja) (vidjeti dio 4.4).
In order to ensure effective erythropoiesis, iron status should be evaluated for all patients prior to and during treatment and supplementary iron therapy may be necessary and conducted in accordance with therapeutic guidelines. 
Da bi se omogućila učinkovita eritropoeza, u svih bolesnika prije i tijekom liječenja valja provjeravati vrijednosti željeza.
Roche 
France Roche
In the presence of hypertension or existing cardiovascular, cerebrovascular or peripheral vascular diseases, the weekly increase in Hb and the target Hb should be determined individually taking into account the clinical picture. 
U slučaju hipertenzije, ili postojećih kardiovaskularnih i cerebrovaskularnih bolesti, ili bolesti perifernih krvnih žila, tjedni porast Hb te ciljnu vrijednost
The recommended initial dose is 30,000 IU per week (corresponding to approximately 450 IU/kg body weight per week, based on an average weighted patient). 
Preporučena početna doza iznosi 30 000 IU tjedno (što za bolesnika prosječne mase iznosi otprilike
(2) Place a 26G needle onto an appropriate single-use syringe (max.1 ml). 
(2) Na odgovarajuću štrcaljku za jednokratnu uporabu (najviše 1 ml) postavite 26G iglu.
Cytotoxic actions of epoetin beta on bone marrow or on human skin cells were not detected. 
Nije zapaženo citotoksično djelovanje epoetina beta na koštanu srž i stanice kože u ljudi.
If an elevated or rising potassium level is observed then consideration should be given to ceasing administration of NeoRecormon until the level has been corrected. 
Ukoliko se zamijete povećane ili rastuće vrijednosti kalija, treba razmisliti o prekidu terapije lijekom NeoRecormon, sve dok se ne izvrši korekcija kalija.
The initial dose for injections into veins is 40 IU per injection for every 1 kg of your body weight, given three times per week. 
Početna doza za injekcije u venu iznosi 40 IU na svaki kilogram Vaše tjelesne mase po injekciji, primijenjeno tri puta tjedno.
10 Wipe the injection site with an alcohol swab and let it air dry for 10 seconds. 
Očistite mjesto injiciranja tupferom natopljenim alkoholom i pričekajte 10 sekundi da se koža sama osuši.
PRCA caused by neutralising anti-erythropoietin antibodies has been reported in association with erythropoietin therapy, including NeoRecormon. 
PRCA uzrokovana neutralizirajućim antieritropoetinskim antitijelima zabilježena je vezano uz terapiju eritropoetinom, uključujući NeoRecormon.